228 related articles for article (PubMed ID: 32918774)
1. Targetable BRAF and RAF1 Alterations in Advanced Pediatric Cancers.
Rankin A; Johnson A; Roos A; Kannan G; Knipstein J; Britt N; Rosenzweig M; Haberberger J; Pavlick D; Severson E; Vergilio JA; Squillace R; Erlich R; Sathyan P; Cramer S; Kram D; Ross J; Miller V; Reddy P; Alexander B; Ali SM; Ramkissoon S
Oncologist; 2021 Jan; 26(1):e153-e163. PubMed ID: 32918774
[TBL] [Abstract][Full Text] [Related]
2. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma.
Palanisamy N; Ateeq B; Kalyana-Sundaram S; Pflueger D; Ramnarayanan K; Shankar S; Han B; Cao Q; Cao X; Suleman K; Kumar-Sinha C; Dhanasekaran SM; Chen YB; Esgueva R; Banerjee S; LaFargue CJ; Siddiqui J; Demichelis F; Moeller P; Bismar TA; Kuefer R; Fullen DR; Johnson TM; Greenson JK; Giordano TJ; Tan P; Tomlins SA; Varambally S; Rubin MA; Maher CA; Chinnaiyan AM
Nat Med; 2010 Jul; 16(7):793-8. PubMed ID: 20526349
[TBL] [Abstract][Full Text] [Related]
3. A novel group of spindle cell tumors defined by S100 and CD34 co-expression shows recurrent fusions involving RAF1, BRAF, and NTRK1/2 genes.
Suurmeijer AJH; Dickson BC; Swanson D; Zhang L; Sung YS; Cotzia P; Fletcher CDM; Antonescu CR
Genes Chromosomes Cancer; 2018 Dec; 57(12):611-621. PubMed ID: 30276917
[TBL] [Abstract][Full Text] [Related]
4. Identification of a novel MTAP-RAF1 fusion in a soft tissue sarcoma.
Hicks JK; Henderson-Jackson E; Duggan J; Joyce DM; Brohl AS
Diagn Pathol; 2018 Oct; 13(1):77. PubMed ID: 30314519
[TBL] [Abstract][Full Text] [Related]
5. A new NFIA:RAF1 fusion activating the MAPK pathway in pilocytic astrocytoma.
Yde CW; Sehested A; Mateu-Regué À; Østrup O; Scheie D; Nysom K; Nielsen FC; Rossing M
Cancer Genet; 2016 Oct; 209(10):440-444. PubMed ID: 27810072
[TBL] [Abstract][Full Text] [Related]
6. Disseminated glioneuronal tumors occurring in childhood: treatment outcomes and BRAF alterations including V600E mutation.
Dodgshun AJ; SantaCruz N; Hwang J; Ramkissoon SH; Malkin H; Bergthold G; Manley P; Chi S; MacGregor D; Goumnerova L; Sullivan M; Ligon K; Beroukhim R; Herrington B; Kieran MW; Hansford JR; Bandopadhayay P
J Neurooncol; 2016 Jun; 128(2):293-302. PubMed ID: 26994902
[TBL] [Abstract][Full Text] [Related]
7. The genetic landscape of ganglioglioma.
Pekmezci M; Villanueva-Meyer JE; Goode B; Van Ziffle J; Onodera C; Grenert JP; Bastian BC; Chamyan G; Maher OM; Khatib Z; Kleinschmidt-DeMasters BK; Samuel D; Mueller S; Banerjee A; Clarke JL; Cooney T; Torkildson J; Gupta N; Theodosopoulos P; Chang EF; Berger M; Bollen AW; Perry A; Tihan T; Solomon DA
Acta Neuropathol Commun; 2018 Jun; 6(1):47. PubMed ID: 29880043
[TBL] [Abstract][Full Text] [Related]
8. CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profiles.
Jain P; Fierst TM; Han HJ; Smith TE; Vakil A; Storm PB; Resnick AC; Waanders AJ
Oncogene; 2017 Nov; 36(45):6348-6358. PubMed ID: 28806393
[TBL] [Abstract][Full Text] [Related]
9. Identification of fusions with potential clinical significance in melanoma.
Moran JMT; Le LP; Nardi V; Golas J; Farahani AA; Signorelli S; Onozato ML; Foreman RK; Duncan LM; Lawrence DP; Lennerz JK; Dias-Santagata D; Hoang MP
Mod Pathol; 2022 Dec; 35(12):1837-1847. PubMed ID: 35871080
[TBL] [Abstract][Full Text] [Related]
10. Melanomas with activating RAF1 fusions: clinical, histopathologic, and molecular profiles.
Williams EA; Shah N; Montesion M; Sharaf R; Pavlick DC; Sokol ES; Alexander BM; Venstrom JM; Elvin JA; Ross JS; Tse JY; Mochel MC
Mod Pathol; 2020 Aug; 33(8):1466-1474. PubMed ID: 32123303
[TBL] [Abstract][Full Text] [Related]
11. Identification of frequent BRAF copy number gain and alterations of RAF genes in Chinese prostate cancer.
Ren G; Liu X; Mao X; Zhang Y; Stankiewicz E; Hylands L; Song R; Berney DM; Clark J; Cooper C; Lu YJ
Genes Chromosomes Cancer; 2012 Nov; 51(11):1014-23. PubMed ID: 22833462
[TBL] [Abstract][Full Text] [Related]
12. Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma.
Jones DT; Kocialkowski S; Liu L; Pearson DM; Ichimura K; Collins VP
Oncogene; 2009 May; 28(20):2119-23. PubMed ID: 19363522
[TBL] [Abstract][Full Text] [Related]
13. Interactome dynamics of RAF1-BRAF kinase monomers and dimers.
Iglesias-Martinez LF; Rauch N; Wynne K; McCann B; Kolch W; Rauch J
Sci Data; 2023 Apr; 10(1):203. PubMed ID: 37045861
[TBL] [Abstract][Full Text] [Related]
14. Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma.
Cin H; Meyer C; Herr R; Janzarik WG; Lambert S; Jones DT; Jacob K; Benner A; Witt H; Remke M; Bender S; Falkenstein F; Van Anh TN; Olbrich H; von Deimling A; Pekrun A; Kulozik AE; Gnekow A; Scheurlen W; Witt O; Omran H; Jabado N; Collins VP; Brummer T; Marschalek R; Lichter P; Korshunov A; Pfister SM
Acta Neuropathol; 2011 Jun; 121(6):763-74. PubMed ID: 21424530
[TBL] [Abstract][Full Text] [Related]
15. Targeting BRAF in pediatric brain tumors.
Kieran MW
Am Soc Clin Oncol Educ Book; 2014; ():e436-40. PubMed ID: 24857135
[TBL] [Abstract][Full Text] [Related]
16. Oncogenic properties via MAPK signaling of the SOX5-RAF1 fusion gene identified in a wild-type NRAS/BRAF giant congenital nevus.
Vinyals A; Ferreres JR; Calbet-Llopart N; Ramos R; Tell-Martí G; Carrera C; Marcoval J; Puig S; Malvehy J; Puig-Butillé JA; Fabra À
Pigment Cell Melanoma Res; 2022 Jul; 35(4):450-460. PubMed ID: 35587097
[TBL] [Abstract][Full Text] [Related]
17. The distribution of BRAF gene fusions in solid tumors and response to targeted therapy.
Ross JS; Wang K; Chmielecki J; Gay L; Johnson A; Chudnovsky J; Yelensky R; Lipson D; Ali SM; Elvin JA; Vergilio JA; Roels S; Miller VA; Nakamura BN; Gray A; Wong MK; Stephens PJ
Int J Cancer; 2016 Feb; 138(4):881-90. PubMed ID: 26314551
[TBL] [Abstract][Full Text] [Related]
18. A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases.
Harding JJ; Catalanotti F; Munhoz RR; Cheng DT; Yaqubie A; Kelly N; McDermott GC; Kersellius R; Merghoub T; Lacouture ME; Carvajal RD; Panageas KS; Berger MF; Rosen N; Solit DB; Chapman PB
Oncologist; 2015 Jul; 20(7):789-97. PubMed ID: 25956405
[TBL] [Abstract][Full Text] [Related]
19. Combined RAF and MEK Inhibition to Treat Activated Non-V600 BRAF-Altered Advanced Cancers.
Rustgi N; Maria A; Toumbacaris N; Zhao H; Kargus K; Bryant M; Waksmundzki A; Aricescu I; Lefkowitz RA; Li BT; Chou J; Capanu M; de Stanchina E; Misale S; Shia J; Yaeger R
Oncologist; 2024 Jan; 29(1):15-24. PubMed ID: 37616543
[TBL] [Abstract][Full Text] [Related]
20. Frequent CD30 Expression in an Emerging Group of Mesenchymal Tumors With NTRK, BRAF, RAF1, or RET Fusions.
Kojima N; Mori T; Motoi T; Kobayashi E; Yoshida M; Yatabe Y; Ichikawa H; Kawai A; Yonemori K; Antonescu CR; Yoshida A
Mod Pathol; 2023 Apr; 36(4):100083. PubMed ID: 36788089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
